We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.84B
AUM Growth
-$861M
Cap. Flow
-$303M
Cap. Flow %
-7.88%
Top 10 Hldgs %
67.4%
Holding
122
New
18
Increased
22
Reduced
23
Closed
17

Top Buys

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$66.5M
2
FOLD
Amicus Therapeutics
FOLD
+$15.4M
3
NIO icon
NIO
NIO
+$12.4M
4
BABA icon
Alibaba
BABA
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$8.3M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$487M
2
BPMC
Blueprint Medicines
BPMC
+$13.9M
3
ONC
BeOne Medicines Ltd
ONC
+$12.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.04M
5
IMUX icon
Immunic
IMUX
+$6.85M

Sector Composition

Rank Sector Weight
1 Healthcare 45.68%
2 Consumer Discretionary 28.3%
3 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$19.8M 0.52%
400,000
-100,000
-20% -$5.09M
TSRO
27
CALL
DELISTED
TESARO, Inc.
TSRO
$19.5M 0.51%
500,000
+150,000
+43% +$5.3M
XNCR icon
28
Xencor
XNCR
$1.71B
$19.5M 0.51%
500,000
+100,000
+25% +$4.08M
BMRN icon
29
CALL
BioMarin Pharmaceuticals
BMRN
$13.3B
$19.4M 0.5%
200,000
– –
XBI icon
30
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$19.2M 0.5%
+200,000
New +$19.4M
MU icon
31
CALL
Micron Technology
MU
$1.07T
$18.1M 0.47%
+400,000
New +$20.2M
MDCO
32
CALL
DELISTED
Medicines Co
MDCO
$17.9M 0.47%
600,000
-100,000
-14% -$3.77M
C icon
33
CALL
Citigroup
C
$233B
$17.9M 0.47%
+250,000
New +$17.7M
IFRX icon
34
InflaRx
IFRX
$296M
$17.2M 0.45%
500,000
– –
ALBO
35
DELISTED
Albireo Pharma Inc
ALBO
$16.5M 0.43%
500,000
– –
BABA icon
36
CALL
Alibaba
BABA
$293B
$16.5M 0.43%
+100,000
New +$17.7M
AUTL
37
Autolus Therapeutics
AUTL
$591M
$15.3M 0.4%
500,000
-25,000
-5% -$675K
KYNB
38
Kyntra Bio
KYNB
$28.5M
$15.2M 0.4%
10,000
– –
SAGE
39
DELISTED
Sage Therapeutics
SAGE
$14.1M 0.37%
100,000
– –
ARGX icon
40
argenx
ARGX
$53.6B
$14M 0.37%
185,000
+35,000
+23% +$3.1M
FCX icon
41
CALL
Freeport-McMoran
FCX
$93.6B
$13.9M 0.36%
1,000,000
– –
WYNN icon
42
CALL
Wynn Resorts
WYNN
$10.5B
$12.7M 0.33%
+100,000
New +$14.8M
AAL icon
43
CALL
American Airlines Group
AAL
$9.97B
$12.4M 0.32%
+300,000
New +$11.7M
NKTR icon
44
CALL
Nektar Therapeutics
NKTR
$2.57B
$12.2M 0.32%
13,333
-6,667
-33% -$5.69M
FOLD
45
CALL
DELISTED
Amicus Therapeutics
FOLD
$12.1M 0.31%
1,000,000
+500,000
+100% +$6.99M
MDCO
46
DELISTED
Medicines Co
MDCO
$12M 0.31%
400,000
– –
AXDX
47
CALL
DELISTED
Accelerate Diagnostics
AXDX
$11.5M 0.3%
50,000
– –
AXDX
48
DELISTED
Accelerate Diagnostics
AXDX
$11.5M 0.3%
50,000
– –
RGNX icon
49
Regenxbio
RGNX
$704M
$11.3M 0.29%
150,000
– –
DNLI icon
50
Denali Therapeutics
DNLI
$3.97B
$10.9M 0.28%
500,000
– –
1
2
3 4 5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q3 2018 Portfolio in Review

As of Q3 2018, Artal Group held 122 positions worth $3.84B, down 18% from $4.71B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Artal Group withdrew a net $303M in Q3 2018, closing 17 positions and reducing 23 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $9.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 36% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Rubius Therapeutics, Inc worth $69.8M.

  • Artal Group's largest Q3 2018 buy was Rubius Therapeutics, Inc: 2,908,791 shares worth $69.8M.
  • Artal Group added most to Amicus Therapeutics in Q3 2018, an estimated $15.4M increase.
  • Artal Group's biggest Q3 2018 reduction was WW International, cutting an estimated $487M.
  • Artal Group fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $9.04M.
  • Artal Group's ten largest holdings make up 67% of its $3.84B portfolio in Q3 2018.
  • Artal Group opened 18 new positions and closed 17 in Q3 2018.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.84B.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.